Constipation News and Research

Latest Constipation News and Research

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

New blood test for early stage ovarian cancer

Australian researchers say they have developed an accurate blood test to detect the first stages of ovarian cancer.

3 Mar 2008

Real-time imaging device may improve surgery for congenital colon disease

Researchers at Cedars-Sinai Medical Center are developing a spectral imaging system that could result in shorter operating times for infants undergoing surgery for Hirschsprung's disease, according to a mouse study reported in the Journal of Biophotonics.

1 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

FDA approves Nexium for gastroesophageal reflux disease in children

The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD).

28 Feb 2008

Brain response differences found in way women with irritable bowel syndrome deal with pain

UCLA researchers found that women with IBS cannot effectively turn-off a pain modulation mechanism in the brain, which causes them to be more sensitive to abdominal pain, compared to women without IBS.

9 Jan 2008

Researchers establish risk factors for Parkinson's disease

Doctors know an impaired sense of smell is an early indicator of Parkinson's Disease.

8 Jan 2008

Placebo better than antipsychotic drugs for treating aggression in the intellectually disabled

Antipsychotic drugs which are commonly used to treat aggression in people who are intellectually disabled have been revealed to be ineffective.

6 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Constipation most common cause of children's abdominal pain

A new study led by a University of Iowa researcher showed that acute and chronic constipation together accounted for nearly half of all cases of acute abdominal pain in children treated at one hospital.

18 Dec 2007

ACG offers updated clinical guidance for managing pregnant patients

Physician experts from the American College of Gastroenterology have released an updated educational monograph highlighting the unique clinical challenges of caring for women with chronic digestive disorders during pregnancy and managing GI complications relating to pregnancy.

10 Dec 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Preventing Morphine tolerance

Tolerance to the pain-relieving effects of morphine - which builds rapidly with prolonged use - can be prevented by blocking a key substance that's formed when the drug is taken, researchers at the Saint Louis University School of Medicine have discovered.

2 Nov 2007

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

The Food and Drug Administration (FDA) in the U.S. has given approval for a new drug to treat chronic myeloid leukemia (CML).

30 Oct 2007

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.

22 Oct 2007

Gastrointestinal disorders and work-related absenteeism

Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.

16 Oct 2007

Nicotine patch for prostate surgery relief?

The use of a nicotine patch - successfully used to help many smokers decrease their dependency on nicotine - was shown to reduce pain in men after prostate removal surgery in a new anesthesiology study.

15 Oct 2007

Colonoscopy most effective screening option for colon cancer

According to the American Society for Gastrointestinal Endoscopy (ASGE), colonoscopy remains the most effective screening option for colorectal cancer.

3 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007